| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we found that point mutations of Fibroblast Growth Factor Receptor 3 (FGFR3) gene and Telomerase Reverse Transcriptase (TERT）gene were prevalent in bladder urothelial carcinomas (54.1% and 71.1%, respectively).These results indicate that point mutations of FGFR3 and TERT gene can be useful markers to detect the presence of tumor cells even in urine samples or small biopsy specimens. Next, we performed modified in situ AS-PCR using BNA clamping method to block amplification of wild-type templates and to increase detection of mutant-type allele, and could detect mutation signals specifically in the paraffin-embedded sections. Although there is still room for improvement, this approach also allows an efficient work flow when a number of mutation assays need to be developed simultaneously.
|
